ChemicalBook > CAS DataBase List > 1,4-Dihydro-4-[3-[[[[3-[4-(3-methoxyphenyl)-1-piperidinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-3,5-pyridinedicarboxylicacid3,5-dimethylesterL-Lactate

1,4-Dihydro-4-[3-[[[[3-[4-(3-methoxyphenyl)-1-piperidinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-3,5-pyridinedicarboxylicacid3,5-dimethylesterL-Lactate

Product Name
1,4-Dihydro-4-[3-[[[[3-[4-(3-methoxyphenyl)-1-piperidinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-3,5-pyridinedicarboxylicacid3,5-dimethylesterL-Lactate
CAS No.
186185-03-5
Chemical Name
1,4-Dihydro-4-[3-[[[[3-[4-(3-methoxyphenyl)-1-piperidinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-3,5-pyridinedicarboxylicacid3,5-dimethylesterL-Lactate
Synonyms
BMS 193885;BMS193885,BMS 193885;BMS-193885 >=98% (HPLC);BMS-193885, 10 mM in DMSO;Dimethyl 4-(3-(3-(3-(4-(3-methoxyphenyl)piperidin-1-yl)propyl)ureido)phenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate;1,4-dihydro-4-[3-[[[[3-[4-(3-methoxyphenyl)-1-piperidinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-3,5-dimethyl ester-3,5-pyridinedicarboxylic acid;3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-[3-[[[[3-[4-(3-methoxyphenyl)-1-piperidinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-, 3,5-dimethyl ester;1,4-Dihydro-4-[3-[[[[3-[4-(3-methoxyphenyl)-1-piperidinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-3,5-pyridinedicarboxylicacid3,5-dimethylesterL-Lactate
CBNumber
CB42518835
Molecular Formula
C33H42N4O6
Formula Weight
590.71
MOL File
186185-03-5.mol
More
Less

1,4-Dihydro-4-[3-[[[[3-[4-(3-methoxyphenyl)-1-piperidinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-3,5-pyridinedicarboxylicacid3,5-dimethylesterL-Lactate Property

Boiling point:
707.5±60.0 °C(Predicted)
Density 
1.188±0.06 g/cm3(Predicted)
storage temp. 
Desiccate at +4°C
solubility 
DMSO: >10mg/mL
pka
13.94±0.46(Predicted)
form 
powder
color 
light yellow to yellow
More
Less

Safety

Hazard Codes 
Xn
Risk Statements 
22
WGK Germany 
3
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
Hazard statements

H302Harmful if swallowed

Precautionary statements

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P270Do not eat, drink or smoke when using this product.

P301+P312IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.

P330Rinse mouth.

P501Dispose of contents/container to..…

More
Less

N-Bromosuccinimide Price

Sigma-Aldrich
Product number
B5063
Product name
BMS-193885
Purity
≥98% (HPLC)
Packaging
5mg
Price
$170
Updated
2025/07/31
Sigma-Aldrich
Product number
B5063
Product name
BMS-193885
Purity
≥98% (HPLC)
Packaging
25mg
Price
$541
Updated
2025/07/31
Tocris
Product number
3242
Product name
BMS193885
Purity
≥99%(HPLC)
Packaging
10
Price
$271
Updated
2021/12/16
Tocris
Product number
3242
Product name
BMS193885
Purity
≥99%(HPLC)
Packaging
50
Price
$1088
Updated
2021/12/16
Usbiological
Product number
254785
Product name
BMS 193885
Packaging
10mg
Price
$531
Updated
2021/12/16
More
Less

1,4-Dihydro-4-[3-[[[[3-[4-(3-methoxyphenyl)-1-piperidinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-3,5-pyridinedicarboxylicacid3,5-dimethylesterL-Lactate Chemical Properties,Usage,Production

Uses

BMS 193885, is a potent, and competitive neuropeptide (NPY) Y1 antagonist, that has also displayed 160-fold selectivity over σ1, α1, Y2, Y4 and Y5 receptors respectively. BMS 193885, is also brain penetrant, and able to reduce food intake and body weight through central Y1 inhibition.

Biological Activity

BMS-193885 is a potent, selective Y1 antagonist th at is active in both acute and chronic animal models of food intake. Although it is active in vivo, it is not orally bioavailable due to poor intestinal absorption, so it is not being pursued for pharmaceutical development. BMS-193885 has been used as a pre-clinical proof of concept tool for showing efficacy of Y1 antagonism in treating obesity.

in vivo

Acute feeding suppression: BMS-193885 (30-50 μg/5 μL; i.c.v.; single dose) blocks NPY (5 μg, 10 μg)-induced feeding in satious Sprague-Dawley rats[1].
Peripheral feeding suppression: BMS-193885 (10 mg/kg; i.p.; single dose) reduces NPY-induced 1-hour food intake and spontaneous nocturnal food intake in male Sprague-Dawley rats[1][2].
Chronic weight loss: BMS-193885 (10 mg/kg; i.p.; once daily for 44 days) reduces cumulative food intake and weight gain in male Sprague-Dawley rats without tolerance[1].
Cardiovascular safety: BMS-193885 (30 mg/kg; i.v.; single dose) had no serious adverse effects on heart rate and blood pressure in conscious rats and anesthetized dogs[1].
BMS-193885 (5 mg/kg; i.p.; single dose) significantly blocked NPY Y1 receptors in Wistar rats and reduced the effects of NPY injection on cardiopulmonary function[3].

Animal Model:Male Sprague-Dawley rats (220-280 g), satiated, with i.c.v. cannula implantation[1]
Dosage:30-50 μg (10% DMSO in sterile Ringer)
Administration:i.c.v. injection (5 μL), single dose
Result:Significantly reduced NPY-induced 1-h food intake by 57% (30 μg) and 63% (50 μg) compared to vehicle controls. No effect was observed on basal food intake1.
Animal Model:Male Sprague-Dawley rats (220-280 g), satiated[1]
Dosage:10 mg/kg (40% PEG 400 + 60% saline)
Administration:i.p. injection, single dose 30 min before dark cycle
Result:Reduced NPY-induced 1-h food intake by 33-57% and spontaneous overnight food intake by 29-54% compared to vehicle.
Animal Model:Male Sprague-Dawley rats (220-280 g), naive[1]
Dosage:10 mg/kg BMS-193885 (40% PEG 400 + 60% saline)
Administration:i.p. injection daily for 44 days, 2 h before dark cycle
Result:Reduced cumulative food intake by 12-15% and suppressed body weight gain by 8.5% compared to vehicle. No tolerance developed, but adhesive peritonitis occurred in some animals.
Animal Model:Conscious male Sprague-Dawley rats (220-280 g); anesthetized dogs[1]
Dosage:30 mg/kg (rats), 10 mg/kg (dogs) (in sterile saline)
Administration:i.v. injection, single dose
Result:No significant changes in heart rate or blood pressure were observed in rats or dogs. Oral bioavailability was <0.1% due to poor absorption[1]1.

IC 50

NPY Y1 receptor; NPY Y1 receptor: 3.3 nM (Ki)

1,4-Dihydro-4-[3-[[[[3-[4-(3-methoxyphenyl)-1-piperidinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-3,5-pyridinedicarboxylicacid3,5-dimethylesterL-Lactate Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

1,4-Dihydro-4-[3-[[[[3-[4-(3-methoxyphenyl)-1-piperidinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-3,5-pyridinedicarboxylicacid3,5-dimethylesterL-Lactate Suppliers

China 28 United Kingdom 1 United States 7 USA 1 Global 37
3B Pharmachem (Wuhan) International Co.,Ltd.
Tel
821-50328103-801 18930552037
Fax
86-21-50328109
Email
3bsc@sina.com
Country
China
ProdList
15838
Advantage
69
EMMX Biotechnology LLC
Tel
888-539-0666
Fax
888-539-0666
Email
info@emmx.com
Country
United States
ProdList
8447
Advantage
60
Shanghai EFE Biological Technology Co., Ltd.
Tel
021-65675885 18964387627
Fax
021-65675885
Email
info@efebio.com
Country
China
ProdList
9803
Advantage
58
Shanghai YuanYe Biotechnology Co., Ltd.
Tel
021-61312847; 18021002903
Fax
QQ:3008007432
Email
3008007409@qq.com
Country
China
ProdList
71826
Advantage
60
Beijing Solarbio Science & Tecnology Co., Ltd.
Tel
010-50973130 18101056239
Email
3193328036@qq.com
Country
China
ProdList
29760
Advantage
68
Fan De(Beijing) Biotechnology Co., Ltd.
Tel
15911056312
Email
liming@bio-fount.com
Country
China
ProdList
9729
Advantage
58
TargetMol Chemicals Inc.
Tel
+1-781-999-5354; +17819995354
Email
marketing@targetmol.com
Country
United States
ProdList
32435
Advantage
58
Energy Chemical
Tel
021-58432009 400-005-6266
Fax
021-58436166
Email
marketing1@energy-chemical.com
Country
China
ProdList
44894
Advantage
58
Hebei Weite Medical Technology Co., Ltd
Tel
13180081292 13180081292
Email
contact@wetogethermed.com
Country
China
ProdList
7942
Advantage
58
Nantong Hi-Future Biotechnology Co., Ltd
Tel
18051384581
Email
sales@chemhifuture.com
Country
China
ProdList
2998
Advantage
58

186185-03-5, 1,4-Dihydro-4-[3-[[[[3-[4-(3-methoxyphenyl)-1-piperidinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-3,5-pyridinedicarboxylicacid3,5-dimethylesterL-LactateRelated Search:


  • 1,4-Dihydro-4-[3-[[[[3-[4-(3-methoxyphenyl)-1-piperidinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-3,5-pyridinedicarboxylicacid3,5-dimethylesterL-Lactate
  • BMS 193885
  • 1,4-dihydro-4-[3-[[[[3-[4-(3-methoxyphenyl)-1-piperidinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-3,5-dimethyl ester-3,5-pyridinedicarboxylic acid
  • 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-[3-[[[[3-[4-(3-methoxyphenyl)-1-piperidinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-, 3,5-dimethyl ester
  • BMS-193885 >=98% (HPLC)
  • BMS193885,BMS 193885
  • Dimethyl 4-(3-(3-(3-(4-(3-methoxyphenyl)piperidin-1-yl)propyl)ureido)phenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
  • BMS-193885, 10 mM in DMSO
  • 186185-03-5
  • C33H42N4O6C3H6O3